CYT News and Press, Cyteir Therapeutics Inc. From 07/10/21

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

RA Capital has taken a 9.4% stake in Cyteir Therapeutics (CYT).The purchase of 3,247,117 shares was made on June 22.Cyteir just began trading on June 18.Cyteir is focused on therapies for solid tumors and blood cancers.Seeking Alpha contributor Donovan Jones has a bullish rating on the stock....

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an ini...

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance International IPO Index was down 3.4% year-to-date, while the ACWX was up 10.4%. For f...

Zolak/iStock via Getty Images Oncology-focused biotech firm Cyteir Therapeutics ([[CYT]]) ended lower on trading debut after rising as much as ~13.8% intraday Friday following an IPO priced at $18.00 per share. Shares opened at $16.50 at about 12:30 PM ET, down ~8.3% from the initial public o...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an ini...